External broker reports(aggregated public sources), Geojit BNP Paribas

Geojit

External broker reports(aggregated public sources)

Equity Bottom-Up

<p>With persistent focus of service parameters and timely turnarounds, DLPL was able to achieve robust growth in volume during the pandemic. Leveraging its dedicated network driven infrastructure and techenabled processes, we expect the company to be able to perform well in the expected third wave situation. Hence, we upgrade our rating on the...</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

With persistent focus of service parameters and timely turnarounds, DLPL was able to achieve robust growth in volume during the pandemic. Leveraging its dedicated network driven infrastructure and techenabled processes, we expect the company to be able to perform well in the expected third wave situation. Hence, we upgrade our rating on the...Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dr. Lal Pathlabs Limited: Significant Rise in COVID Testing

India

Dr. Lal PathLabs Limited operates clinical laboratories. The Company offers medical diagnostic, cardiology, radiology, pathology and imaging, health checkup, blood test, and customer care services. Dr. Lal PathLabs conducts its business in India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dr Lal PathLabs Ltd (DLPL IN)

Dr. Lal Pathlabs Limited: Significant Rise in COVID Testing

With persistent focus of service parameters and timely turnarounds, DLPL was able to achieve robust growth in volume during the pandemic....

Geojit

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)